Abstract
Blood-brain barrier (BBB) leakage and brain edema is a critical part of stroke pathophysiology. In this mini-review, we briefly survey the potential role of matrix metalloproteinases (MMPs) in BBB dysfunction. A large body of data in both experimental models as well as clinical patient populations suggests that MMPs may disrupt BBB permeability and interfere with cell-cell signaling in the neurovascular unit. Hence, ongoing efforts are underway to validate MMPs as potential biomarkers in stroke as well as pursue MMP blockers as therapeutic opportunities. Because BBB perturbations may also occur in neurodegeneration, MMPs and associated neurovascular unit mechanisms may also be potential targets in a broader range of CNS disorders.
Keywords: Brain edema, neuroprotection, neurodegeneration, neurovascular unit, stroke recovery, Blood-brain barrier (BBB), matrix metalloproteinases (MMPs), BBB permeability, biomarkers, CNS disorders.
Current Pharmaceutical Design
Title:Neurovascular Matrix Metalloproteinases and the Blood-Brain Barrier
Volume: 18 Issue: 25
Author(s): Ji Hae Seo, Shuzhen Guo, Josephine Lok, Deepti Navaratna, Michael J. Whalen, Kyu-Won Kim and Eng H. Lo
Affiliation:
Keywords: Brain edema, neuroprotection, neurodegeneration, neurovascular unit, stroke recovery, Blood-brain barrier (BBB), matrix metalloproteinases (MMPs), BBB permeability, biomarkers, CNS disorders.
Abstract: Blood-brain barrier (BBB) leakage and brain edema is a critical part of stroke pathophysiology. In this mini-review, we briefly survey the potential role of matrix metalloproteinases (MMPs) in BBB dysfunction. A large body of data in both experimental models as well as clinical patient populations suggests that MMPs may disrupt BBB permeability and interfere with cell-cell signaling in the neurovascular unit. Hence, ongoing efforts are underway to validate MMPs as potential biomarkers in stroke as well as pursue MMP blockers as therapeutic opportunities. Because BBB perturbations may also occur in neurodegeneration, MMPs and associated neurovascular unit mechanisms may also be potential targets in a broader range of CNS disorders.
Export Options
About this article
Cite this article as:
Hae Seo Ji, Guo Shuzhen, Lok Josephine, Navaratna Deepti, J. Whalen Michael, Kim Kyu-Won and H. Lo Eng, Neurovascular Matrix Metalloproteinases and the Blood-Brain Barrier, Current Pharmaceutical Design 2012; 18 (25) . https://dx.doi.org/10.2174/138161212802002742
DOI https://dx.doi.org/10.2174/138161212802002742 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Membrane and Soluble Forms of Endoglin in Preeclampsia
Current Molecular Medicine Current Developments of Coumarin Compounds in Medicinal Chemistry
Current Pharmaceutical Design Applications of Nanocarbons in Bio-Medical Devices
Recent Innovations in Chemical Engineering Innate Inflammatory Responses in Stroke: Mechanisms and Potential Therapeutic Targets
Current Medicinal Chemistry Bronchiolitis Care in the Hospital
Reviews on Recent Clinical Trials Oxidative Stress in the Molecular Mechanism of Pathogenesis at Different Diseased States of Organism in Clinics and Experiment
Current Drug Targets - Inflammation & Allergy 23Na Magnetic Resonance Imaging for the Determination of Myocardial Viability: The Status and the Challenges
Current Vascular Pharmacology Polyphenols and Neuroprotection against Ischemia and Neurodegeneration
Mini-Reviews in Medicinal Chemistry Glioblastoma Multiforme Imaging: The Role of Nuclear Medicine
Current Radiopharmaceuticals Novel and Emerging Drugs for Acute Lymphoblastic Leukemia
Current Cancer Drug Targets Torasemide for the Treatment of Heart Failure
Cardiovascular & Hematological Disorders-Drug Targets Dendritic Cells and their Receptors in Antitumor Immune Response
Current Molecular Medicine Multiple Sclerosis and Neuroinflammation: The Overview of Current and Prospective Therapies
Current Pharmaceutical Design Hypoxia-inducible Factor (HIF) in Hormone Signaling During Health and Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Neurotrophic Factors for Retinal Ganglion Cell Neuropathy - With a Special Reference to Diabetic Neuropathy in the Retina
Current Diabetes Reviews Editorial
Recent Patents on Drug Delivery & Formulation Current Updates in the Medical Management of Obesity
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Adenosine Neuromodulation and Traumatic Brain Injury
Current Neuropharmacology Review: Therapeutic Targeting of HMGB1 in Stroke
Current Drug Delivery PDE4D Gene in the STRK1 Region on 5q12: Susceptibility Gene for Ischemic Stroke
Current Medicinal Chemistry